Treat to Target in Axial Spondyloarthritis

Published:August 17, 2019DOI:https://doi.org/10.1016/j.rdc.2019.07.003

      Keywords

      To read this article in full you will need to make a payment
      Purchase one-time access
      Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.
      Content published before 2002 is available via pay-per-view purchase only.
      Subscribe to Rheumatic Disease Clinics
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Jacques P.
        • Lambrecht S.
        • Verheugen E.
        • et al.
        Proof of concept: enthesitis and new bone formation in spondyloarthritis are driven by mechanical strain and stromal cells.
        Ann Rheum Dis. 2014; 73: 437-445
        • Benjamin M.
        • McGonagle D.
        The anatomical basis for disease localisation in seronegative spondyloarthropathy at entheses and related sites.
        J Anat. 2001; 199 (Available at:) (Accessed March 4, 2019): 503-526
        • Reveille J.D.
        • Witter J.P.
        • Weisman M.H.
        Prevalence of axial spondylarthritis in the United States: estimates from a cross-sectional survey.
        Arthritis Care Res (Hoboken). 2012; 64: 905-910
        • Costantino F.
        • Talpin A.
        • Said-Nahal R.
        • et al.
        Prevalence of spondyloarthritis in reference to HLA-B27 in the French population: results of the GAZEL cohort.
        Ann Rheum Dis. 2015; 74: 689-693
        • Bakland G.
        • Alsing R.
        • Singh K.
        • et al.
        Assessment of SpondyloArthritis International Society criteria for axial spondyloarthritis in chronic back pain patients with a high prevalence of HLA-B27.
        Arthritis Care Res (Hoboken). 2013; 65: 448-453
        • Boonen A.
        • Chorus A.
        • Miedema H.
        • et al.
        Withdrawal from labour force due to work disability in patients with ankylosing spondylitis.
        Ann Rheum Dis. 2001; 60 (Available at:) (Accessed May 13, 2017): 1033-1039
        • Castillo-Ortiz J.D.
        • Ramiro S.
        • Landewé R.
        • et al.
        Work outcome in patients with ankylosing spondylitis: results from a 12-year followup of an international study.
        Arthritis Care Res (Hoboken). 2016; 68: 544-552
        • Rudwaleit M.
        • Haibel H.
        • Baraliakos X.
        • et al.
        The early disease stage in axial spondylarthritis: results from the German Spondyloarthritis Inception Cohort.
        Arthritis Rheum. 2009; 60: 717-727
        • van Tubergen A.
        The changing clinical picture and epidemiology of spondyloarthritis.
        Nat Rev Rheumatol. 2015; 11: 110-118
        • Jaakkola E.
        • Herzberg I.
        • Laiho K.
        • et al.
        Finnish HLA studies confirm the increased risk conferred by HLA-B27 homozygosity in ankylosing spondylitis.
        Ann Rheum Dis. 2006; 65: 775-780
        • Sieper J.
        • Poddubnyy D.
        Axial spondyloarthritis.
        Lancet. 2017; 390: 73-84
        • Dougados M.
        • Etcheto A.
        • Molto A.
        • et al.
        Clinical presentation of patients suffering from recent onset chronic inflammatory back pain suggestive of spondyloarthritis: the DESIR cohort.
        Joint Bone Spine. 2015; 82: 345-351
        • Garrett S.
        • Jenkinson T.
        • Kennedy L.G.
        • et al.
        A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index.
        J Rheumatol. 1994; 21: 2286-2291
        • Machado P.
        • Landewé R.
        • Lie E.
        • et al.
        Ankylosing spondylitis disease activity score (ASDAS): defining cut-off values for disease activity states and improvement scores.
        Ann Rheum Dis. 2011; 70: 47-53
        • Smolen J.S.
        • Schöls M.
        • Braun J.
        • et al.
        Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force.
        Ann Rheum Dis. 2018; 77: 3-17
        • van der Heijde D.
        • Ramiro S.
        • Landewé R.
        • et al.
        2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis.
        Ann Rheum Dis. 2017; 76: 978-991
        • Rudwaleit M.
        • van der Heijde D.
        • Landewe R.
        • et al.
        The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection.
        Ann Rheum Dis. 2009; 68: 777-783
        • van der Linden S.
        • Valkenburg H.A.
        • Cats A.
        Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria.
        Arthritis Rheum. 1984; 27 (Available at:) (Accessed February 23, 2019): 361-368
        • Dougados M.
        • van der Linden S.
        • Juhlin R.
        • et al.
        The European Spondylarthropathy Study Group preliminary criteria for the classification of spondylarthropathy.
        Arthritis Rheum. 1991; 34 (Available at:) (Accessed February 23, 2019): 1218-1227
        • Amor B.
        • Dougados M.
        • Mijiyawa M.
        Criteria of the classification of spondylarthropathies.
        Rev Rhum Mal Osteoartic. 1990; 57 ([in French]. Available at:) (Accessed February 23, 2019): 85-89
        • Poddubnyy D.
        • van Tubergen A.
        • Landewé R.
        • et al.
        Assessment of SpondyloArthritis international Society (ASAS). Development of an ASAS-endorsed recommendation for the early referral of patients with a suspicion of axial spondyloarthritis.
        Ann Rheum Dis. 2015; 74: 1483-1487
        • Riddle M.C.
        • Rosenstock J.
        • Gerich J.
        • Insulin Glargine 4002 Study Investigators
        The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients.
        Diabetes Care. 2003; 26: 3080-3086
        • Cannon C.P.
        The IDEAL cholesterol.
        JAMA. 2005; 294: 2492
        • Putrik P.
        • Ramiro S.
        • Moltó A.
        • et al.
        Individual-level and country-level socioeconomic determinants of disease outcomes in SpA: multinational, cross-sectional study (ASAS-COMOSPA).
        Ann Rheum Dis. 2019; https://doi.org/10.1136/annrheumdis-2018-214259
        • Nikiphorou E.
        • van der Heijde D.
        • Norton S.
        • et al.
        Inequity in biological DMARD prescription for spondyloarthritis across the globe: results from the ASAS-COMOSPA study.
        Ann Rheum Dis. 2017; https://doi.org/10.1136/annrheumdis-2017-212457
        • Haraoui B.
        • Smolen J.S.
        • Aletaha D.
        • et al.
        Treating rheumatoid arthritis to target: multinational recommendations assessment questionnaire.
        Ann Rheum Dis. 2011; 70: 1999-2002
        • Vermeer M.
        • Kuper H.H.
        • Bernelot Moens H.J.
        • et al.
        Adherence to a treat-to-target strategy in early rheumatoid arthritis: results of the DREAM remission induction cohort.
        Arthritis Res Ther. 2012; 14: R254
        • Gvozdenović E.
        • Allaart C.F.
        • van der Heijde D.
        • et al.
        When rheumatologists report that they agree with a guideline, does this mean that they practise the guideline in clinical practice? Results of the International Recommendation Implementation Study (IRIS).
        RMD Open. 2016; 2: e000221
        • Brouwers M.C.
        • Kho M.E.
        • Browman G.P.
        • et al.
        AGREE II: advancing guideline development, reporting and evaluation in health care.
        CMAJ. 2010; 182: E839-E842
        • Sieper J.
        • van der Heijde D.
        • Dougados M.
        • et al.
        Efficacy and safety of adalimumab in patients with non-radiographic axial spondyloarthritis: results of a randomised placebo-controlled trial (ABILITY-1).
        Ann Rheum Dis. 2013; 72: 815-822
        • Haibel H.
        • Rudwaleit M.
        • Listing J.
        • et al.
        Efficacy of adalimumab in the treatment of axial spondylarthritis without radiographically defined sacroiliitis: results of a twelve-week randomized, double-blind, placebo-controlled trial followed by an open-label extension up to week fifty-two.
        Arthritis Rheum. 2008; 58: 1981-1991
        • Barkham N.
        • Keen H.I.
        • Coates L.C.
        • et al.
        Clinical and imaging efficacy of infliximab in HLA-B27-Positive patients with magnetic resonance imaging-determined early sacroiliitis.
        Arthritis Rheum. 2009; 60: 946-954
        • Smolen J.S.
        • Braun J.
        • Dougados M.
        • et al.
        Treating spondyloarthritis, including ankylosing spondylitis and psoriatic arthritis, to target: recommendations of an international task force.
        Ann Rheum Dis. 2014; 73: 6-16
        • Danve A.
        • Deodhar A.
        Treat to target in axial spondyloarthritis: what are the issues?.
        Curr Rheumatol Rep. 2017; 19: 22
        • Machado P.M.M.C.
        • Landewé R.B.M.
        • van der Heijde D.M.
        • et al.
        Endorsement of definitions of disease activity states and improvement scores for the Ankylosing Spondylitis Disease Activity Score: results from OMERACT 10.
        J Rheumatol. 2011; 38: 1502-1506
        • Machado P.
        • Landewé R.
        Spondyloarthritis: is it time to replace BASDAI with ASDAS?.
        Nat Rev Rheumatol. 2013; 9: 388-390
        • Machado P.M.
        • Landewé R.
        • Heijde D.V.
        • Assessment of SpondyloArthritis international Society (ASAS)
        Ankylosing Spondylitis Disease Activity Score (ASDAS): 2018 update of the nomenclature for disease activity states.
        Ann Rheum Dis. 2018; 77: 1539-1540
        • Machado P.
        • Landewé R.B.M.
        • Braun J.
        • et al.
        MRI inflammation and its relation with measures of clinical disease activity and different treatment responses in patients with ankylosing spondylitis treated with a tumour necrosis factor inhibitor.
        Ann Rheum Dis. 2012; 71: 2002-2005
        • Ramiro S.
        • van der Heijde D.
        • van Tubergen A.
        • et al.
        Higher disease activity leads to more structural damage in the spine in ankylosing spondylitis: 12-year longitudinal data from the OASIS cohort.
        Ann Rheum Dis. 2014; 73: 1455-1461
        • Husic R.
        • Gretler J.
        • Felber A.
        • et al.
        Disparity between ultrasound and clinical findings in psoriatic arthritis.
        Ann Rheum Dis. 2014; 73: 1529-1536
        • Michelsen B.
        • Diamantopoulos A.P.
        • Hammer H.B.
        • et al.
        Ultrasonographic evaluation in psoriatic arthritis is of major importance in evaluating disease activity.
        Ann Rheum Dis. 2016; 75: 2108-2113
        • Mandl P.
        • Navarro-Compán V.
        • Terslev L.
        • et al.
        EULAR recommendations for the use of imaging in the diagnosis and management of spondyloarthritis in clinical practice.
        Ann Rheum Dis. 2015; 74: 1327-1339
        • Lambert R.G.W.
        • Bakker P.A.C.
        • van der Heijde D.
        • et al.
        Defining active sacroiliitis on MRI for classification of axial spondyloarthritis: update by the ASAS MRI working group.
        Ann Rheum Dis. 2016; 75: 1958-1963
        • Hermann K.-G.A.
        • Baraliakos X.
        • van der Heijde D.M.
        • et al.
        Descriptions of spinal MRI lesions and definition of a positive MRI of the spine in axial spondyloarthritis: a consensual approach by the ASAS/OMERACT MRI study group.
        Ann Rheum Dis. 2012; 71: 1278-1288
        • Weber U.
        • Lambert R.G.W.
        • Østergaard M.
        • et al.
        The diagnostic utility of magnetic resonance imaging in spondylarthritis: an international multicenter evaluation of one hundred eighty-seven subjects.
        Arthritis Rheum. 2010; 62: 3048-3058
        • Lambert R.G.W.
        • Salonen D.
        • Rahman P.
        • et al.
        Adalimumab significantly reduces both spinal and sacroiliac joint inflammation in patients with ankylosing spondylitis: a multicenter, randomized, double-blind, placebo-controlled study.
        Arthritis Rheum. 2007; 56: 4005-4014
        • Sepriano A.
        • Regel A.
        • van der Heijde D.
        • et al.
        Efficacy and safety of biological and targeted-synthetic DMARDs: a systematic literature review informing the 2016 update of the ASAS/EULAR recommendations for the management of axial spondyloarthritis.
        RMD Open. 2017; 3: e000396
        • Sieper J.
        • Lenaerts J.
        • Wollenhaupt J.
        • et al.
        Efficacy and safety of infliximab plus naproxen versus naproxen alone in patients with early, active axial spondyloarthritis: results from the double-blind, placebo-controlled INFAST study, Part 1.
        Ann Rheum Dis. 2014; 73: 101-107
        • Sieper J.
        • Lenaerts J.
        • Wollenhaupt J.
        • et al.
        Maintenance of biologic-free remission with naproxen or no treatment in patients with early, active axial spondyloarthritis: results from a 6-month, randomised, open-label follow-up study, INFAST Part 2.
        Ann Rheum Dis. 2014; 73: 108-113
        • Wanders A.
        • Heijde Dv
        • Landewé R.
        • et al.
        Nonsteroidal antiinflammatory drugs reduce radiographic progression in patients with ankylosing spondylitis: a randomized clinical trial.
        Arthritis Rheum. 2005; 52: 1756-1765
        • Kroon F.
        • Landewé R.
        • Dougados M.
        • et al.
        Continuous NSAID use reverts the effects of inflammation on radiographic progression in patients with ankylosing spondylitis.
        Ann Rheum Dis. 2012; 71: 1623-1629
        • Sieper J.
        • Listing J.
        • Poddubnyy D.
        • et al.
        Effect of continuous versus on-demand treatment of ankylosing spondylitis with diclofenac over 2 years on radiographic progression of the spine: results from a randomised multicentre trial (ENRADAS).
        Ann Rheum Dis. 2016; 75: 1438-1443
        • Poddubnyy D.
        • Rudwaleit M.
        • Haibel H.
        • et al.
        Effect of non-steroidal anti-inflammatory drugs on radiographic spinal progression in patients with axial spondyloarthritis: results from the German Spondyloarthritis Inception Cohort.
        Ann Rheum Dis. 2012; 71: 1616-1622
        • Baraliakos X.
        • Kiltz U.
        • Peters S.
        • et al.
        Efficiency of treatment with non-steroidal anti-inflammatory drugs according to current recommendations in patients with radiographic and non-radiographic axial spondyloarthritis.
        Rheumatology. 2017; 56: 95-102
        • Maxwell L.J.
        • Zochling J.
        • Boonen A.
        • et al.
        TNF-alpha inhibitors for ankylosing spondylitis.
        Cochrane Database Syst Rev. 2015; (CD005468)
        • van der Heijde D.
        • Landewé R.
        • Baraliakos X.
        • et al.
        Radiographic findings following two years of infliximab therapy in patients with ankylosing spondylitis.
        Arthritis Rheum. 2008; 58: 3063-3070
        • van der Heijde D.
        • Landewé R.
        • Einstein S.
        • et al.
        Radiographic progression of ankylosing spondylitis after up to two years of treatment with etanercept.
        Arthritis Rheum. 2008; 58: 1324-1331
        • Baraliakos X.
        • Haibel H.
        • Listing J.
        • et al.
        Continuous long-term anti-TNF therapy does not lead to an increase in the rate of new bone formation over 8 years in patients with ankylosing spondylitis.
        Ann Rheum Dis. 2014; 73: 710-715
        • Molnar C.
        • Scherer A.
        • Baraliakos X.
        • et al.
        TNF blockers inhibit spinal radiographic progression in ankylosing spondylitis by reducing disease activity: results from the Swiss Clinical Quality Management cohort.
        Ann Rheum Dis. 2018; 77: 63-69
        • van der Heijde D.
        • Sieper J.
        • Maksymowych W.P.
        • et al.
        Clinical and MRI remission in patients with nonradiographic axial spondyloarthritis who received long-term open-label adalimumab treatment: 3-year results of the ABILITY-1 trial.
        Arthritis Res Ther. 2018; 20: 61
        • van der Heijde D.
        • Joshi A.
        • Pangan A.L.
        • et al.
        ASAS40 and ASDAS clinical responses in the ABILITY-1 clinical trial translate to meaningful improvements in physical function, health-related quality of life and work productivity in patients with non-radiographic axial spondyloarthritis.
        Rheumatology. 2016; 55: 80-88
        • Van den Bosch F.
        • Mease P.J.
        • Sieper J.
        • et al.
        Long-term efficacy and predictors of remission following adalimumab treatment in peripheral spondyloarthritis: 3-year results from ABILITY-2.
        RMD Open. 2018; 4: e000566
        • Rudwaleit M.
        • van der Heijde D.
        • Landewé R.
        • et al.
        The Assessment of SpondyloArthritis International Society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general.
        Ann Rheum Dis. 2011; 70: 25-31
        • Sieper J.
        • van der Heijde D.
        • Dougados M.
        • et al.
        Early response to adalimumab predicts long-term remission through 5 years of treatment in patients with ankylosing spondylitis.
        Ann Rheum Dis. 2012; 71: 700-706
        • Schipper L.G.
        • Fransen J.
        • den Broeder A.A.
        • et al.
        Time to achieve remission determines time to be in remission.
        Arthritis Res Ther. 2010; 12: R97
        • Carron P.
        • Varkas G.
        • Cypers H.
        • et al.
        Anti-TNF-induced remission in very early peripheral spondyloarthritis: the CRESPA study.
        Ann Rheum Dis. 2017; 76: 1389-1395
        • Kruithof E.
        • De Rycke L.
        • Roth J.
        • et al.
        Immunomodulatory effects of etanercept on peripheral joint synovitis in the spondylarthropathies.
        Arthritis Rheum. 2005; 52: 3898-3909
        • Marzo-Ortega H.
        • McGonagle D.
        • O’Connor P.
        • et al.
        Efficacy of etanercept in the treatment of the entheseal pathology in resistant spondylarthropathy: a clinical and magnetic resonance imaging study.
        Arthritis Rheum. 2001; 44: 2112-2117
        • Meyer A.
        • Chatelus E.
        • Wendling D.
        • et al.
        Safety and efficacy of anti-tumor necrosis factor α therapy in ten patients with recent-onset refractory reactive arthritis.
        Arthritis Rheum. 2011; 63: 1274-1280
        • Mease P.
        • Sieper J.
        • Van den Bosch F.
        • et al.
        Randomized controlled trial of adalimumab in patients with nonpsoriatic peripheral spondyloarthritis.
        Arthritis Rheumatol. 2015; 67: 914-923
        • Paramarta J.E.
        • De Rycke L.
        • Heijda T.F.
        • et al.
        Efficacy and safety of adalimumab for the treatment of peripheral arthritis in spondyloarthritis patients without ankylosing spondylitis or psoriatic arthritis.
        Ann Rheum Dis. 2013; 72: 1793-1799
        • Coates L.C.
        • Moverley A.R.
        • McParland L.
        • et al.
        Effect of tight control of inflammation in early psoriatic arthritis (TICOPA): a UK multicentre, open-label, randomised controlled trial.
        Lancet. 2015; 386: 2489-2498
        • Landewé R.
        • Sieper J.
        • Mease P.
        • et al.
        Efficacy and safety of continuing versus withdrawing adalimumab therapy in maintaining remission in patients with non-radiographic axial spondyloarthritis (ABILITY-3): a multicentre, randomised, double-blind study.
        Lancet. 2018; 392: 134-144
        • Landewé R.
        • Braun J.
        • Deodhar A.
        • et al.
        Efficacy of certolizumab pegol on signs and symptoms of axial spondyloarthritis including ankylosing spondylitis: 24-week results of a double-blind randomised placebo-controlled Phase 3 study.
        Ann Rheum Dis. 2014; 73: 39-47
        • Sieper J.
        • Landewé R.
        • Rudwaleit M.
        • et al.
        Effect of certolizumab pegol over ninety-six weeks in patients with axial spondyloarthritis: results from a phase III randomized trial.
        Arthritis Rheumatol. 2015; 67: 668-677
        • Braun J.
        • Baraliakos X.
        • Hermann K.-G.
        • et al.
        Effect of certolizumab pegol over 96 weeks of treatment on inflammation of the spine and sacroiliac joints, as measured by MRI, and the association between clinical and MRI outcomes in patients with axial spondyloarthritis.
        RMD Open. 2017; 3: e000430
        • van der Heijde D.
        • Dougados M.
        • Landewé R.
        • et al.
        Sustained efficacy, safety and patient-reported outcomes of certolizumab pegol in axial spondyloarthritis: 4-year outcomes from RAPID-axSpA.
        Rheumatology. 2017; 56: 1498-1509
        • van der Heijde D.
        • Baraliakos X.
        • Hermann K.-G.A.
        • et al.
        Limited radiographic progression and sustained reductions in MRI inflammation in patients with axial spondyloarthritis: 4-year imaging outcomes from the RAPID-axSpA phase III randomised trial.
        Ann Rheum Dis. 2018; 77: 699-705
        • Baeten D.
        • Sieper J.
        • Braun J.
        • et al.
        Secukinumab, an interleukin-17A inhibitor, in ankylosing spondylitis.
        N Engl J Med. 2015; 373: 2534-2548
        • van der Heijde D.
        • Cheng-Chung Wei J.
        • Dougados M.
        • et al.
        Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological disease-modifying anti-rheumatic drugs (COAST-V): 16 week results of a phase 3 randomised, double-blind, active-controlled and placebo-controlled trial.
        Lancet. 2018; 392: 2441-2451
        • Mazurov V.
        • Erdes S.
        • Kunder E.
        • et al.
        Efficacy and safety of BCD-085, a novel il-17 inhibitor, in ankylosing spondylitis. Results of phase 2 clinical study.
        Ann Rheum Dis. 2018; 77: A64
        • Deodhar A.
        • Gensler L.S.
        • Sieper J.
        • et al.
        Three multicenter, randomized, double-blind, placebo-controlled studies evaluating the efficacy and safety of ustekinumab in axial spondyloarthritis.
        Arthritis Rheumatol. 2019; 71: 258-270
        • van der Heijde D.
        • Deodhar A.
        • Wei J.C.
        • et al.
        Tofacitinib in patients with ankylosing spondylitis: a phase II, 16-week, randomised, placebo-controlled, dose-ranging study.
        Ann Rheum Dis. 2017; 76: 1340-1347
        • van der Heijde D.
        • Baraliakos X.
        • Gensler L.S.
        • et al.
        Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active ankylosing spondylitis (TORTUGA): results from a randomised, placebo-controlled, phase 2 trial.
        Lancet. 2018; 392: 2378-2387
        • Weiß A.
        • Song I.-H.
        • Haibel H.
        • et al.
        Good correlation between changes in objective and subjective signs of inflammation in patients with short- but not long duration of axial spondyloarthritis treated with tumor necrosis factor-blockers.
        Arthritis Res Ther. 2014; 16: R35
        • Baraliakos X.
        • Koenig A.S.
        • Jones H.
        • et al.
        Predictors of Clinical remission under anti-tumor necrosis factor treatment in patients with ankylosing spondylitis: pooled analysis from large randomized clinical trials.
        J Rheumatol. 2015; 42: 1418-1426
        • Rudwaleit M.
        • Claudepierre P.
        • Wordsworth P.
        • et al.
        Effectiveness, safety, and predictors of good clinical response in 1250 patients treated with adalimumab for active ankylosing spondylitis.
        J Rheumatol. 2009; 36: 801-808
        • Vastesaeger N.
        • van der Heijde D.
        • Inman R.D.
        • et al.
        Predicting the outcome of ankylosing spondylitis therapy.
        Ann Rheum Dis. 2011; 70: 973-981
        • Arends S.
        • Brouwer E.
        • van der Veer E.
        • et al.
        Baseline predictors of response and discontinuation of tumor necrosis factor-alpha blocking therapy in ankylosing spondylitis: a prospective longitudinal observational cohort study.
        Arthritis Res Ther. 2011; 13: R94
        • Rios Rodriguez V.
        • Hermann K.-G.
        • Weiß A.
        • et al.
        Progression of the structural damage in the sacroiliac joints in patients with early axial spondyloarthritis during a long-term anti-TNF treatment: six-year results of the ESTHER trial.
        Arthritis Rheumatol. 2019; https://doi.org/10.1002/art.40786
        • Navarro-Compán V.
        • Plasencia-Rodríguez C.
        • de Miguel E.
        • et al.
        Anti-TNF discontinuation and tapering strategies in patients with axial spondyloarthritis: a systematic literature review.
        Rheumatology (Oxford). 2016; 55: 1188-1194
        • Baraliakos X.
        • Listing J.
        • Fritz C.
        • et al.
        Persistent clinical efficacy and safety of infliximab in ankylosing spondylitis after 8 years--early clinical response predicts long-term outcome.
        Rheumatology (Oxford). 2011; 50: 1690-1699